Sarepta names former AbbVie president CEO as Ingram retires

• Severino brings extensive pharma experience from senior roles at AbbVie, Amgen, and Merck, and will join Sarepta's board while Ingram remains in an advisory role through 2026
• Under Ingram's leadership, Sarepta secured multiple Duchenne muscular dystrophy treatment approvals, but its gene therapy Elevidys was linked to two patient deaths
• The company recently discontinued several gene therapy programs for limb-girdle muscular dystrophy amid operational challenges

Sarepta Therapeutics CEO Transition Summary

Key Leadership Change:

Sarepta Therapeutics announced Monday that Michael Severino will become CEO effective July 28, replacing Doug Ingram, who is retiring after leading the company since 2017. Severino, former AbbVie vice-chairman and president and most recently CEO of Tessera Therapeutics, will also join Sarepta's board. Ingram will remain in an advisory role through end of 2026 to facilitate the transition.

Company Performance Under Ingram:

During Ingram's tenure, Sarepta secured multiple approvals for Duchenne muscular dystrophy (DMD) treatments. However, the company faced significant challenges with Elevidys, the first approved gene therapy for DMD, which was linked to two patient deaths. Additionally, Sarepta recently discontinued several gene therapy programs for limb-girdle muscular dystrophy.

New CEO Background:

Severino brings extensive pharmaceutical industry experience, having overseen research and development and corporate strategy at AbbVie. He has also held senior positions at Amgen and Merck, providing strong credentials in drug development and strategic leadership.

Market Implications:

The leadership transition comes at a critical juncture for Sarepta as the rare disease drugmaker navigates safety concerns with its flagship gene therapy and portfolio restructuring. The appointment follows a board-led search, suggesting a planned succession rather than an abrupt departure. Severino's R&D expertise may signal a focus on strengthening pipeline development and addressing safety protocols. Investors will likely monitor how the new leadership manages ongoing Elevidys safety issues and advances the company's remaining DMD treatment portfolio.